Esperion Therapeutics to Host Conference Call on September 3, 2013 to Announce Top-line Results from a Phase 2 Clinical Study...
August 30 2013 - 4:00PM
Business Wire
Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of hypercholesterolemia, today
announced that it will host a conference call and webcast on
Tuesday, September 3, 2013 at 8:30 a.m. Eastern Time (ET) to
present top-line results from a Phase 2a clinical study of its lead
product candidate, ETC-1002, as an add-on to statin therapy in
patients with hypercholesterolemia.
The live event will be accessible on the Esperion website
beginning at 8:30 a.m. at www.esperion.com, under the Investors
section, or by calling (877) 312-7508 (domestic) or (253) 237-1184
(international). The access code is 28976349. A replay of the event
will be available beginning at approximately 10:00 a.m. ET on
September 3, 2013 from the Esperion website or by calling (855)
859-2056 (domestic) or (404) 537-3406 (international), using access
code 28976349. The replay will be available through September 17,
2013.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a biopharmaceutical company
focused on the research, development and commercialization of
therapies for the treatment of patients with elevated levels of
LDL-C and other cardiometabolic risk factors. ETC-1002, Esperion's
lead product candidate, is a unique, first-in-class, orally
available, once-daily small molecule designed to lower levels of
LDL-C and to avoid side effects associated with existing LDL-C
lowering therapies. ETC-1002 is targeted for statin intolerant
patients with elevated levels of LDL-C. Esperion has completed
seven clinical studies to date, including four Phase 2a studies,
and expects to initiate a robust Phase 2b clinical program in the
fourth quarter of 2013. For more information, please visit
www.esperion.com.
Forward Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding the anticipated
timing of Esperion’s Phase 2b clinical program. Any statements
contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward-looking statements involve risks and uncertainties that
could cause Esperion's actual results to differ significantly from
those projected, including, without limitation, the risk that
unanticipated developments could interfere with the development
(and commercialization) of ETC-1002, as well as other risks
detailed in Esperion's filings with the Securities and Exchange
Commission, including our Quarterly Report on Form 10-Q filed with
Securities and Exchange Commission on August 12, 2013. You are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date of this release.
Esperion disclaims any obligation or undertaking to update or
revise any forward-looking statements contained in this press
release, other than to the extent required by law.
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024